Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria

Journal of Clinical Investigation

Volumn 124, Issue 10, 2014, Pages 4529-4538

  Shen, Wenyi ^a,b   Clemente, Michael J ^a   Hosono, Naoko ^a   Yoshida, Kenichi ^c   Przychodzen, Bartlomiej ^a   Yoshizato, Tetsuichi ^c   Shiraishi, Yuichi ^d   Miyano, Satoru ^d   Ogawa, Seishi ^c   Maciejewski, Jaroslaw P ^a   Makishima, Hideki ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; MUCIN 7; PROTEIN; PROTEIN SUZ 12; PROTEIN TET 2; PROTEIN U2AF1; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; JAK2 PROTEIN, HUMAN; MEMBRANE PROTEIN; NUCLEAR PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL GLYCAN-CLASS A PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; RIBONUCLEOPROTEIN; SUZ12 PROTEIN, HUMAN; TET2 PROTEIN, HUMAN; U2AF1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CARCINOGENESIS; CHILD; CLONAL EVOLUTION; CLONOGENIC ASSAY; EXOME; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; FRAMESHIFT MUTATION; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY LOSS; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; SOMATIC MUTATION; TRISOMY 8; GENETICS; HEMOLYSIS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; NUCLEOTIDE SEQUENCE; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; EXOME; FEMALE; FLOW CYTOMETRY; HEMOGLOBINURIA, PAROXYSMAL; HEMOLYSIS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JANUS KINASE 2; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYCOMB REPRESSIVE COMPLEX 2; PROTO-ONCOGENE PROTEINS; RIBONUCLEOPROTEINS; YOUNG ADULT;

EID: 84907494617     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI74747     Document Type: Article

References (48)

1. Brodsky RA. Paroxysmal nocturnal hemoglobinuria: stem cells and clonality. Hematology Am Soc Hematol Educ Program. 2008;111-115.
2. Takeda J, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73(4):703-711.
3. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia. Blood. 2006;108(8):2509-2519.
4. Maciejewski JP, Sloand EM, Sato T, Anderson S, Young NS. Impaired hematopoiesis in paroxysmal nocturnal hemoglobinuria/aplastic anemia is not associated with a selective proliferative defect in the glycosylphosphatidylinositol-anchored protein-deficient clone. Blood. 1997;89(4):1173-1181.
5. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A. 1999;96(9):5209-5214.
6. Inoue N, et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006;108(13):4232-4236.
7. O'Keefe CL, et al. Deletions of Xp22.2 including PIG-A locus lead to paroxysmal nocturnal hemoglobinuria. Leukemia. 2011;25(2):379-382.
8. Mortazavi Y, Tooze JA, Gordon-Smith EC, Rutherford TR. N-RAS gene mutation in patients with aplastic anemia and aplastic anemia/paroxysmal nocturnal hemoglobinuria during evolution to clonal disease. Blood. 2000;95(2):646-650.
9. Sugimori C, et al. Paroxysmal nocturnal hemoglobinuria and concurrent JAK2 (V617F) mutation. Blood Cancer J. 2012;2(3):e63.
10. Walter MJ, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090-1098.
11. Ley TJ, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008;456(7218):66-72.
12. Bessler M, Mason P, Hillmen P, Luzzatto L. omatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet. 1994;343(8903):951-953.
13. Mazelin L, et al. Netrin-1 controls colorectal tumorigenesis by regulating apoptosis. Nature. 2004;431(7004):80-84.
14. Arakawa H. Netrin-1 and its receptors in tumorigenesis. Nat Rev Cancer. 2004;4(12):978-987.
15. Van Gils JM, et al. The neuroimmune guidance cue netrin-1 promotes atherosclerosis by inhibiting the emigration of macrophages from plaques. Nat Immunol. 2012;13(2):136-143.
16. Cavard C, et al. Gene expression profiling provides insights into the pathways involved in solid pseudopapillary neoplasm of the pancreas. J Pathol. 2009;218(2):201-209.
17. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501(7467):338-345.
18. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature. 2013;501(7467):328-337.
19. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061-1068.
20. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059-2074.
21. Stransky N, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011;333(6046):1157-1160.
22. Graubert TA, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2011;44(1):53-57.
23. Makishima H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012;119(14):3203-3210.
24. Ko M, et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature. 2010;468(7325):839-843.
25. Koh SS, et al. Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Mod Pathol. 2012;25(6):828-837.
26. Shima H, et al. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion. Int J Hematol. 2014;99(1):21-31.
27. Sun HT, Cheng SX, Tu Y, Li XH, Zhang S. FoxQ1 promotes glioma cells proliferation and migration by regulating NRXN3 expression. PLoS One. 2013;8(1):e55693.
28. Kim JY, et al. KDM3B is the H3K9 demethylase involved in transcriptional activation of lmo2 in leukemia. Mol Cell Biol. 2012;32(14):2917-2933.
29. Liu L, Sanchez-Bonilla M, Crouthamel M, Giachelli C, Keel S. Mice lacking the sodium-dependent phosphate import protein, PiT1 (SLC20A1), have a severe defect in terminal erythroid differentiation and early B cell development. Exp Hematol. 2013;41(5):432-443.
30. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):77-99.
31. Cheung KJ, et al. High resolution analysis of follicular lymphoma genomes reveals somatic recurrent sites of copy-neutral loss of heterozygosity and copy number alterations that target single genes. Genes Chromosomes Cancer. 2010;49(8):669-681.
32. Summers KM, et al. Experimental and bioinformatic characterisation of the promoter region of the Marfan syndrome gene, FBN1. Genomics. 2009;94(4):233-240.
33. Liu C, et al. SUZ12 is involved in progression of non-small cell lung cancer by promoting cell proliferation metastasis. Tumour Biol. 2014;35(6):6073-6082.
34. Abdel-Wahab O, Dey A. The ASXL-BAP1 axis: new factors in myelopoiesis, cancer and epigenetics. Leukemia. 2013;27(1):10-15.
35. Panagopoulos I, et al. Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation. Genes Chromosomes Cancer. 2013;52(7):610-618.
36. Parsyan A, et al. The helicase protein DHX29 promotes translation initiation, cell proliferation, and tumorigenesis. Proc Natl Acad Sci U S A. 2009;106(52):22217-22222.
37. Roy S, et al. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Br J Haematol. 2012;157(4):446-456.
38. Gomez-Segui I, et al. Novel recurrent mutations in the RAS-like GTP-binding gene RIT1 in myeloid malignancies. Leukemia. 2013;27(9):1943-1946.
39. Kralovics R, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790.
40. Rollinson S, Richards S, Norfolk D, Bibi K, Morgan G, Hillmen P. Both paroxysmal nocturnal hemoglobinuria (PNH) type II cells and PNH type III cells can arise from different point mutations involving the same codon of the PIG-A gene. Blood. 1997;89(8):3069-3071.
41. Krawitz PM, et al. A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT. Blood. 2013;122(7):1312-1315.
42. Parker C, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106(12):3699-3709.
43. Maciejewski JP, Tiu RV, O'Keefe C. Application of array-based whole genome scanning technologies as a cytogenetic tool in haematological malignancies. Br J Haematol. 2009;146(5):479-488.
44. Gondek LP, et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. Blood. 2008;111(3):1534-1542.
45. Tiu RV, et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol. 2009;27(31):5219-5226.
46. Yoshida K, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-69.
47. Robinson JT, et al. Integrative genomics viewer. Nat Biotechnol. 2011;29(1):24-26.
48. Makishima H, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013;45(8):942-946.